Company profile: CarThera
1.1 - Company Overview
Company description
- Provider of therapeutic ultrasound-based medical devices for treating brain disorders, including SonoCloud, an intracranial implant that uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier for enhanced delivery of therapeutic agents, and SonoCloud-9, a nine-emitter version to open larger regions; also conducts preclinical and clinical R&D combining SonoCloud with therapeutic agents to treat brain tumors and neurodegenerative diseases.
Products and services
- Research & Development: Ongoing preclinical-and-clinical program architects combinations of SonoCloud technology with diverse therapeutic agents to treat brain tumors and neurodegenerative diseases, advancing drug penetration across the BBB
- SonoCloud: An intracranial implant engineers low-intensity pulsed ultrasound to temporarily open the blood-brain barrier, enabling significantly increased concentrations of therapeutic molecules to reach targeted brain tissue
- SonoCloud-9: A nine-emitter device constructs larger-region blood-brain barrier openings for improved drug delivery in brain diseases, expanding coverage versus SonoCloud to elevate therapeutic agent access
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CarThera
RadiaDyne
HQ: United States
Website
- Description: Provider of medical diagnostics and devices; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RadiaDyne company profile →
Eikonoklastes
HQ: United States
Website
- Description: Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eikonoklastes company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
ProCure
HQ: United States
Website
- Description: Provider of a network of proton therapy centers in the United States, offering proton therapy including pencil beam scanning; physician case evaluations; initial consultation and planning; treatment sessions typically 5 days a week for 4–7 weeks; and regular radiation oncologist check-ins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProCure company profile →
Storm Therapeutics
HQ: United Kingdom
Website
- Description: Provider of RNA-modifying enzyme–targeted therapeutics and discovery platforms, including STC-15, an oral METTL3 inhibitor for oncology; a drug discovery and RNA analytics platform to identify targets and develop small-molecule candidates for oncology, inflammation, viral infections, and CNS diseases; and a target discovery platform using chemical biology, RNA sequencing, RNA mass spectrometry, and functional genomics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Storm Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CarThera
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CarThera
2.2 - Growth funds investing in similar companies to CarThera
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CarThera
4.2 - Public trading comparable groups for CarThera
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →